On July 4, 2024, Philogen S.p.A. ( and Sun Pharmaceutical Industries Limited announced via a stock exchange filing that the European Medicines Agency (EMA) had accepted their application to approve Nidlegy™. The application was submitted on June 3, and it has now entered the validation phase by the EMA. “The validation of the dossier by …